Dr. Timothy D. Mcclure, M.D.
Interventional Radiology (Vascular & Interventional Radiology Physician)
- Medicare participating
At a glance
- Medical school
- University of Washington School of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 523
Licensed in California since 2006, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: University of Washington School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Vascular & Interventional Radiology Physician primary
CA license A95976 (first issued 2006; current) -
Diagnostic Radiology Physician
CA license A95976 (first issued 2006; current) -
Urology Physician
CA license A95976 (first issued 2006; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
- Hospital for Special Surgery New York, NY
Medical groups
- Weill Medical College of Cornell (2,051 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 523
- Services billed
- 1,267
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 255 | 213 |
| Established patient office or other outpatient visit, 30-39 minutes | 188 | 150 |
| Ultrasound scan of pelvic region through rectum | 123 | 123 |
| Biopsy of prostate gland | 113 | 113 |
| Insertion of needle into vein for collection of blood sample | 49 | 46 |
| Review by radiologist of ct guidance for needle placement | 46 | 45 |
| New patient office or other outpatient visit, 30-44 minutes | 42 | 42 |
| New patient office or other outpatient visit, 45-59 minutes | 41 | 41 |
| Ultrasound measurement of bladder capacity after voiding | 41 | 35 |
| Needle biopsy of kidney | 40 | 39 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 6 companies reported 21 payments worth $17,515 in total to this clinician.
| Telix Pharmaceuticals | $13,837 |
|---|---|
| Pfizer Inc. | $2,880 |
| GE Healthcare | $500 |
| Galvanize Therapeutics, Inc | $140 |
| Angiodynamics, Inc. | $122 |
| Argon Medical Devices, Inc. | $36.43 |
| Consulting Fee | $13,318 |
|---|---|
| Travel and Lodging | $3,081 |
| Food and Beverage | $1,117 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jan 23, 2025 | Consulting Fee TALZENNA · ONCOLOGY | $2,880 |
| Telix Pharmaceuticals Aug 7, 2025 | Travel and Lodging travel to NEW ORLEANS, LA | $2,438 |
| Telix Pharmaceuticals Aug 7, 2025 | Consulting Fee | $2,438 |
| Telix Pharmaceuticals Aug 7, 2025 | Consulting Fee | $2,250 |
| Telix Pharmaceuticals Aug 7, 2025 | Consulting Fee | $2,250 |
| Telix Pharmaceuticals Sep 11, 2025 | Consulting Fee ILLUCCIX · PROSTATE CANCER DIAGNOSIS | $1,500 |
| Telix Pharmaceuticals Sep 11, 2025 | Consulting Fee ILLUCCIX · PROSTATE CANCER DIAGNOSIS | $1,500 |
| GE Healthcare Jul 16, 2025 | Consulting Fee OEC · Imaging - Molecular Imaging Surgical Imaging | $500 |
| Telix Pharmaceuticals Jun 23, 2025 | Travel and Lodging travel to NEW ORLEANS, LA | $328 |
| Telix Pharmaceuticals Jun 13, 2025 | Travel and Lodging ILLUCCIX; ILLUCCIX · PROSTATE CANCER DIAGNOSIS · travel to NEW ORLEANS, LA | $316 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $276,281 in research payments for these studies, mostly to the institutions running them.
- RTIRE IIT
Angiodynamics, Inc. - Escape - evaluation of prostate specific membrane antigen positron emission tomography-computed tomography in active surveillance for prostate cancer
Progenics Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.